Abstract P2-10-28: COMPASS-TNBC - A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety and anti-tumor activity of novel therapeutics in patients with early relapsed mTNBC. Module 1: Dato-DXd & Module 2: Dato-DXd + durvalumab
Year: 2025
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Thomas Grinda, Rasha Cheikh-Hussin, Magali Lacroix-Triki, Kamar Serhal, Chayma Bousrih, Elie Rassy, Francoise Farace, Marianne Oulhen, Jean-Luc Perfettini, Awatef Allouch, Guillaume Montagnac, Fernanda Mosele, Ines Vaz-Luis, Joana M Ribeiro, Alessandro Viansone, Benjamin Verret, Suzette Delaloge, Jacqueline Deneuve, Claude Coutier, Juliette Gouenard, Fabrice André, Stefan Michiels, Barbara Pistilli
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4411286307